Cell cycle regulator p27 mediates body mass index effects in ovarian cancer in FIGO-stages I-II

1Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: The aim of the present study was to evaluate the association between body mass index (BMI), the biomarker p27, and the clinical factors in FIGOstages I-II ovarian cancer. Patients and Methods: A total of 128 patients with ovarian cancer were included in the study. For testing differences in univariate analyzes we used the Pearson's Chi-square test and the log-rank test. For multivariate analyses the logistic regression and Cox regression models were used with recurrent disease and disease-free survival as endpoints, respectively. Results: Patients with BMI ≤25 kg/m2 had a significantly better 5-year disease-free survival compared with patients with BMI >25 kg/m2 in the total series of patients (p=0.008), and in the series of patients (n=77) with non-serous tumors (p=0.047). Patients with p27-positive non-serous tumors had higher survival compared to patients with p27-negative nonserous tumors (p=0.020). Conclusion: The cell cycle regulator p27 mediates BMI effects in ovarian cancer in FIGO-stages I-II.

Cite

CITATION STYLE

APA

Skirnisdottir, I., Akerud, H., Seidal, T., & Sundstrom-Poromaa, I. (2019). Cell cycle regulator p27 mediates body mass index effects in ovarian cancer in FIGO-stages I-II. Cancer Genomics and Proteomics, 16(6), 443–450. https://doi.org/10.21873/cgp.20148

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free